Evidence map›Paper›PMID 42476129›Full record

ArticleCell2026

A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.

Meredith N Nix, Sai Gourisankar, Kevin J Bowman, Sabin A Nettles, Haopeng Yang, Brendan G Dwyer, Roman C Sarott, Hind Abuzaid, Michael M Martinez, Nick Phillips and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Proteomics-Driven Strategies for Proximity-Inducing Drug Discovery.Angewandte Chemie (International ed. in English) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Meredith N NixDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA; Department of Chemistry, Stanford University, Stanford, CA, USA.
Sai GourisankarDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Kevin J BowmanDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sabin A NettlesDepartment of Pathology, Stanford University, Stanford, CA, USA.
Haopeng YangDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brendan G DwyerDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Roman C SarottDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Hind AbuzaidDepartment of Pathology, Stanford University, Stanford, CA, USA.
Michael M MartinezDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Nick PhillipsDepartment of Cancer Biology, Stanford University, Stanford, CA, USA.
Vincent CabaudDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Artur HakobyanDeep Origin, South San Francisco, CA, USA.
Vahram ArakelovDeep Origin, South San Francisco, CA, USA.
Garik PetrosyanDeep Origin, South San Francisco, CA, USA.
Aram DavtyanDeep Origin, South San Francisco, CA, USA.
Yanlan WangDepartment of Pathology, Stanford University, Stanford, CA, USA.
Juste M SimanauskaiteDepartment of Pathology, Stanford University, Stanford, CA, USA.
Bryan A RomeroDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Hannah M JonesDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Andrey KrokhotinDepartment of Pathology, Stanford University, Stanford, CA, USA.
Tara N LowensohnDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Lei ChenDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
Cara LowDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Hannes VogelDepartment of Pathology, Stanford University, Stanford, CA, USA.
Mark M DavisDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
Daniel FernandezMacromolecular Structure, Nucleus at Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
Tinghu ZhangDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Michael R GreenDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mgreen5@mdanderson.org.
Stephen M HinshawDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA. Electronic address: hinshaw@stanford.edu.
Nathanael S GrayDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA. Electronic address: nsgray01@stanford.edu.
Gerald R CrabtreeDepartment of Pathology, Stanford University, Stanford, CA, USA; Department of Developmental Biology, Stanford University, Stanford, CA, USA. Electronic address: crabtree@stanford.edu.

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Ritimukta Sarangi · 2020 to 2026
$43.3M
ATP-Dependent Chromatin Remodeling in Human MalignancyR01CA163915 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree · 2012 to 2026
$5.4M
Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP InactivationR01CA201380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Richard Green · 2016 to 2026
$3.5M
HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCLR01CA276167 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree, NATHANAEL Schiander GRAY · 2023 to 2026
$2.2M
Small molecule regulation of endogenous transcription factors for circuit-specific neuromodulationRF1MH126720 · NIMH · STANFORD UNIVERSITY · PI CRABTREE, GERALD R. · 2021 to 2021
$1.3M
500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709k
REWIRING ONCOGENIC PATHWAYS TO INDUCE CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIAR01CA304428 · NCI · STANFORD UNIVERSITY · PI Gerald R. Crabtree, Neil E Kay · 2026 to 2026
$661k
Sciex 6500+ QTrap Mass SpectrometerS10OD030332 · OD · SCRIPPS FLORIDA · PI CAMERON, MICHAEL DARIN · 2021 to 2021
$486k
Rewiring fusion oncogenes to activate apoptosisK99CA296700 · NCI · STANFORD UNIVERSITY · PI Sai Gourisankar · 2025 to 2026
$271k
NCI NIH HHS K99 CA296700NCI NIH HHS R01 CA163915NCI NIH HHS R01 CA201380NCI NIH HHS R01 CA276167NCI NIH HHS R01 CA304428NIGMS NIH HHS P30 GM133894NIH HHS S10 OD028697NIH HHS S10 OD030332NIMH NIH HHS RF1 MH126720
6 · The paper itself

Abstract

Developing cancer therapies that induce specific death of malignant cells is critical for preventing relapse. Highly effective strategies, such as immunotherapy, exemplify this principle. Here, we provide the mechanistic basis for a small-molecule approach that leverages chemically induced proximity (CIP) to kill diffuse large B cell lymphoma, the most common non-Hodgkin lymphoma. We developed lysine acetyltransferase (KAT)-based TCIPs (transcriptional/epigenetic chemical inducers of proximity), or KAT-TCIPs, which redirect p300/CREB-binding protein (CBP) to activate cell-death networks repressed by the oncogenic driver BCL6. Our lead KAT-TCIP reprograms the epigenome to initiate apoptosis. The crystal structure of the chemically induced p300-BCL6 complex reveals how chance protein-protein interactions may be exploited to confer the potency and selectivity of KAT-TCIPs. Thus, oncogenic drivers can be co-opted to activate robust cell death. Consistent with their gain-of-function mechanism, TCIPs recruiting different transcriptional activators-p300, BRD4, or CDK9-produce distinct genomic responses, suggesting specialized therapeutic uses.

Indexed as

Lymphoma, Large B-Cell, DiffuseLysine AcetyltransferasesAnimalsApoptosisBromodomain Containing ProteinsCell DeathCREB-Binding ProteinHumansOncogenesp300-CBP Transcription FactorsProto-Oncogene Proteins c-bcl-6Transcription FactorsBCL6 protein, humanBromodomain Containing ProteinsCREB-Binding ProteinLysine Acetyltransferasesp300-CBP Transcription FactorsProto-Oncogene Proteins c-bcl-6Transcription FactorsBCL6chemically induced proximityCIPDLBCLlymphomalysine acetyltransferasestranscription

Identifiers

PMID42476129
PMCPMC13592201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.